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. One year later, penicillin-resistant strains of U. nonliquefaciens were reported (Rosenthal et al. 1978) . According to most authors, the frequency of i3-lactamase production among clinical isolates of B. catarrhalis has increased rapidly; in Sweden the incidence climbed from 4% in 1977 to 42% in 1985 (table I) . Figures as high as 76% for i3-lactamase production have been reported in B. catarrhalis isolates from children with acute otitis media in the United States (Kovatch et al. 1983; Shurin et al. 1983 ).
According to available data, the most common i3-lactamase produced by B. catarrhalis, BRO-l, is plasmid mediated. The same enzyme occurs in M.
nonliquefaciens, a commensal in the upper respiratory tract (Kamme et al. 1984) . BRO-l differs from other characterised plasmid-mediated i3-lactamases in Gram-negative bacteria in its isoelectric focusing pattern and substrate profile (Buu HoiDang Van et al. 1978; Kamme et al. 1984; Matthew et al. 1979 ). It is not yet known if the structural gene encoding BRO-l is located on a transposable element.
The first i3-lactamase-producing strains of B. catarrhalis were recognised in 1977 (Malmvall et al.
(j-Lactamase Production in Upper Respiratory Tract Pathogens
Several aerobic and anaerobic bacterial species found in the upper respiratory tract produce i3-lacUpper Respiratory Tract Infection tamase (Brook & Gober 1984; Knudsin & Miller 1964; Scheifele et al. 1982; Turner & Nord 1983 (J- lactamases, and to investigate the ecological relationship of the plasmids encoding these enzymes .
In 50 children aged 1 to 15 years (mean 4.7 years) undergoing adenoidectomy, specimens for culture were collected from the nasopharynx, nasal conchae and throat, and from the surface and disintegrated tissue of the removed adenoids. None of the children had any recorded history of antibiotic treatment during the 2 months prior to sur- BRO-l and TEM-l are each carried by at least two bacterial species. In each set, one species is pathogenic and may cause respiratory disease in man.
The non-pathogenic species seem to constitute a major source of these determinants in the upper respiratory tract, with a proven potential capacity for their transfer to the pathogenic species. This has previously been reported for H. parainjluenzae (Scheifele et al. 1982) .
The incidence of BRO-l and TEM-l carriage was 34% and 46%, respectively ( fig. 1 ). It is notable that, although none of.·the children received antibiotics for 2 months prior to the collection of the specimens, 60% harboured BRO-l-or TEM-l-pro- Upper Respiratory Tract Infection ducing strains or both in the upper respiratory tract (Eliasson et aI. 1985) .
Selective Effect of Penicillins
Phenoxymethy1penicillin and the aminopenicillins cause selection of ~-lactamase-producing nasopharyngeal pathogens as well as aerobic and anaerobic commensals in the throat (Brook & Gober 1984; Freijd & Rynnel-Dagoo 1983; Karma et at. 1983; Scheifele & Fussell 1981; Syriopoulou et al. 1978) . A spread of ~-lactamase-producing strains, including anaerobes, to healthy household contacts has been reported, which indicates that ~-lacta mase-producing strains can establish themselves in a new host without the ecological benefits of antibiotic treatment (Brook & Gober 1984) . A significantly higher isolation rate of ~-lactamase-produc ing H. inj1uenzae occurs with the aminopenicillins than with phenoxymethylpenicillin (Freijd & Rynnel-Dagoo 1983; Scheifele & Fussell 1981) . The concept that ampicillin, especially the wellabsorbed ampicillin esters, and amoxycillin promote the selection of ~-lactamase-producing strains more than phenoxymethylpenicillin is consistent with the in vitro activity of the drugs against ~ lactamase-negative strains; ampicillin is 8 to 16 times more active than phenoxymethylpenicillin against ~-lactamase-negative B. catarrhalis and H. influenzae (table II) [Kamme 1969 [Kamme , 1970 (table II) . In a previously described investigation, children with a history of recurrent acute otitis media who were likely to have received repeated courses of phenoxymethylpenicillin had a significantly higher isolation rate of ~-lactamase producing B. catarrhalis than children without such a history. No significant difference was noted for H. inj1uenzae in this respect (Eliasson et aI. 1985) .
This supports the view that phenoxymethylpenicillin acts as a stronger selective agent for BRO-l production in B. catarrhalis than for TEM-1 production in H. inj1uenzae. The findings also indicate a long-standing selective effect exerted by this drug on ~-lactamase production by B. catarrhalis.
Clinical Significance of fJ-Lactamase Production
Acute otitis media (AOM) is the only infection in the upper respiratory tract where the aetiologica1 role of B. catarrhalis is established without doubt (Coffey 1966; Coffey et aI. 1967; Howie et at. 1970; Kamme et aI. 1971; . In secretory otitis media (SOM), the middle ear is continuously invaded by the same bacteria which cause AOM; however, the possible value of antimicrobial agents in SOM is not documented (Kamme & Nilsson 1984) . Similarly, in acute sinusitis the aetiological role of B. catarrhalis is still uncertain (Schremer 1984) . Further, Schalen et at. (1985) recently demonstrated that phenoxymethylpenicillin does not influence the course of acute laryngitis in adults, which is a disorder related to nasopharyngeal colonisation of B. catarrhalis (Schalen et at. 1980 (Kamme 1985) . At a frequency of p-lactamase production by H. influenzae of 5 to 10% and by B. catarrhalis of 40 to 60%, the risk that the aetiological agent is a p-lactamase-producing strain remains only 5 to 9% among consecutive primary cases of AOM. This incidence seems to be acceptable and does not indicate the use of drugs other than the penicillins as the primary choice, even if most infections caused by p-lactamase-producing strains would result in therapeutic failure (absent or unsatisfactory response during therapy). However, the correlation between p-lactamase production and therapeutic failure in penicillin or ampicillin treatment of AOM is not established. In 31 children with therapeutic failure after ampicillin or amoxycillin treatment, only 2 failures could be attributed to p-lactamase-producing H. influenzae (Teele et al. 1981) . Similarly, among 14 cases of AOM caused by B. catarrhalis, 2 failures occurred during ampicillin or amoxycillin treatment. In only 1 of these was a p-lactamase-producing B. catarrhalis recovered from the ear exudate, despite evidence that 76% of the strains were p-lactamase producers (Kovatch et al. 1983 ).
In 5 of 7 patients with AOM, who had therapeutic failure while taking phenoxymethylpenicillin, p-lactamase-negative H. injluenzae was isolated from the ear exudate or from the nasopharynx or both. The only other pathogen isolated was a 13-lactamase-producing B. catarrhalis obtained from the nasopharynx of a patient who had a pure culture of H. influenzae in the ear exudate (Laurin et al. 1985) . According to these reports, p-lactamase production in B. catarrhalis, as in H. influenzae, seems to be of marginal clinical significance in the treatment of AOM with penicillins. However, although this may be valid for other upper respiratory tract infections, p-lactamase production can obviously cause therapeutic failure with severe consequences in more serious infections such as pneumonia and exacerbations of chronic bronchitis (Johnson et al. 1981; Ninane et al. 1978; Srinivasan et al. 1981) .
The high frequency of p-lactamase production in commensals and pathogens of the upper respiratory tract has also to be considered from the 119 viewpoint of possible indirect pathogenicity (Maddocks 1980) . Anaerobic bacteria and Staphylococcus aureus have been incriminated as 'protectors' which render penicillin therapy of group A streptococcal tonsillitis ineffective (Brook & Yocum 1984; Knudsin & Miller 1964; Tuner & Nord 1983 ). p-Lactamase-producing H. parainfluenzae and species of Neisseriaceae found in the throat may also be clinically significant in this context Pintado et al. 1985; Scheifele et al. 1982 ).
Therapeutic Aspects
As previously mentioned, no data conclusively support the use of p-lactamase-stable drugs either in primary cases of AOM or in therapeutic failure of AOM primarily treated with phenoxymethylpenicillin or ampicillin. The aminopenicillins do not offer any therapeutic advantage over phenoxymethylpenicillin in primary cases of AOM, and treatment with phenoxymethylpenicillin seems preferable from the ecological point of view (Puhakka et al. 1982; Qvamberg 1981) . In therapeutic failure caused by a p-lactamase-producing strain, co-trimoxazole has been recommended (Schwartz et al. 1982) .
Upper respiratory tract infections are the main indications for penicillins; however, many of the prescriptions written for these drugs are not clinically justified. Undoubtedly, the ecological pressure caused by the penicillins could be reduced by such measures as correct handling of reliable kits for the diagnosis of streptococcal pharyngitis. Further, a 50% overdiagnosis of AOM can be avoided by simply examining the tympanic membrane, preferably by otomicroscopy (Ingvarsson 1982) . In Sweden, with a population of 8 million, approximately 700,000 visits per year to open ward departments are caused by symptoms suggestive of AOM (Laurin et al. 1985) . In the United Kingdom, a 50% overdiagnosis of AOM would mean at least 2 million inappropriate prescriptions of antibiotics yearly.
The duration of therapy is also important. In the treatment of AOM, reduction of the usual 8 to 10 days of therapy to 5 days allows the healing rate to be maintained without increasing the number of complications (Ingvarsson & Lundgren 1982) .
